2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Melanoma
23
Neoplasms
19
Neoplasm Metastasis
19
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
13
Skin Neoplasms
12
Recurrence
10
Head and Neck Neoplasms
10
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Squamous Cell
8
Carcinoma, Basal Cell
8
Breast Neoplasms
8
Urinary Bladder Neoplasms
7
Carcinoma, Merkel Cell
7
Triple Negative Breast Neoplasms
6
Colonic Neoplasms
6
Carcinoma
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Sarcoma
5
Pancreatic Neoplasms
5
Glioblastoma
5
Stomach Neoplasms
4
Multiple Myeloma
4
Mouth Neoplasms
4
Fallopian Tube Neoplasms
4
Interventions
Sorafenib
68
Bevacizumab
44
Oxaliplatin
25
Doxorubicin
22
Gemcitabine
21
Fluorouracil
21
Radiosurgery
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
lenvatinib
17
Cisplatin
17
Capecitabine
17
atezolizumab
14
Leucovorin
14
Hepatectomy
14
Radiotherapy
12
tremelimumab
10
Irinotecan
10
Drug Therapy
10
Cyclophosphamide
10
Carboplatin
10
Blood Specimen Collection
10
Ipilimumab
9
regorafenib
8
Liver Transplantation
8
Everolimus
8
Cryosurgery
8
Chemotherapy, Adjuvant
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
cemiplimab
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled